Abstract
Formulation development of combination drug products requires the
availability of a rapid analytical method with low limits of detection,
for the high-throughput analysis of the large number of samples generated.
Salmeterol xinafoate (SX) and fluticasone propionate (FP) are coformulated
for the treatment of asthma and COPD. RP-HPLC using C-
18 bonded phases of basic compounds, such as SX, can be problematic
due to the occurrence of poor peak shapes. This can be overcome by
decreasing the flow rate, modifying column temperature, careful selection
of the column and use of methanol as organic modifier (McCalley
1999, 2000, 2002). The aim of this study was to examine the performance
of SX on a second-generation silica bonded reverse-phase column,
with a mobile phase containing a high content of organic modifier.
availability of a rapid analytical method with low limits of detection,
for the high-throughput analysis of the large number of samples generated.
Salmeterol xinafoate (SX) and fluticasone propionate (FP) are coformulated
for the treatment of asthma and COPD. RP-HPLC using C-
18 bonded phases of basic compounds, such as SX, can be problematic
due to the occurrence of poor peak shapes. This can be overcome by
decreasing the flow rate, modifying column temperature, careful selection
of the column and use of methanol as organic modifier (McCalley
1999, 2000, 2002). The aim of this study was to examine the performance
of SX on a second-generation silica bonded reverse-phase column,
with a mobile phase containing a high content of organic modifier.
| Original language | English |
|---|---|
| Article number | 180P |
| Pages (from-to) | S81 |
| Number of pages | 1 |
| Journal | Journal of Pharmacy and Pharmacology |
| Volume | 57 |
| Issue number | Supp 1 |
| DOIs | |
| Publication status | Published - Sept 2005 |